6307-70-6

Basic information

• Product Name: 2,6-dimethyl-3-nitrobenzoic acid
• Synonyms: 2,6-Dimethyl-3-nitrobenzoic acid; benzoic acid, 2,6-dimethyl-3-nitro-
• CAS NO: 6307-70-6
• Molecular Formula: C₉H₉NO₄
• Molecular Weight: 195.1721
• Mol File: 6307-70-6.mol

Chemical Properties

• Boiling Point: 358.2°C at 760 mmHg
• Flash Point: 158.7°C
• Density: 1.333g/cm³
• Vapor Pressure: 9.41E-06mmHg at 25°C
• Refractive Index: 1.589
• CAS DataBase Reference: 2,6-dimethyl-3-nitrobenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-dimethyl-3-nitrobenzoic acid(6307-70-6)
• EPA Substance Registry System: 2,6-dimethyl-3-nitrobenzoic acid(6307-70-6)

Safety Data

• Hazardous Substances Data: 6307-70-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2,6-dimethyl-3-nitrobenzoic acid is used as an intermediate in the synthesis of various pharmaceuticals for its ability to be chemically modified to produce a range of medicinal compounds.
Used in Dye Industry:
It serves as an intermediate in the production of dyes, where its chemical structure contributes to the color properties of the final product.
Used in Agrochemical Industry:
2,6-dimethyl-3-nitrobenzoic acid is used as a key component in the production of some herbicides and insecticides, leveraging its chemical properties to control or kill unwanted plants and insects.
Used in Organic Compounds Synthesis:
It is utilized as an intermediate in the synthesis of other organic compounds, highlighting its versatility in organic chemistry for creating a variety of end products.

Upstream product

• 632-46-2 2,6-dimethylbenzoic acid 

Downstream Products

• 82617-29-6 2,6-dimethyl-3-nitrobenzene-1-methanol 
• 6307-78-4 3-Nitro-2,6-dimethyl-benzoylchlorid 
• 26829-85-6 methyl 3-fluoro-2,6-dimethylbenzoate 
• 86246-57-3 (3-amino-2,6-dimethylphenyl)methanol 
• 1292688-03-9 3-(tert-butyldimethylsilyloxy)-2,6-dimethylbenzyl alcohol 
• 1292688-21-1 ethyl 2-(3-(2,6-dimethyl-3-nitrobenzyloxy)phenyl)acetate 
• 1292687-98-9 2-(3-(2,6-dimethyl-3-nitrobenzyloxy)phenyl)acetic acid 
• 1292688-19-7 ethyl 2-(3-(3-methoxy-2,6-dimethylbenzyloxy)-4-methylphenyl)acetate 
• 93351-36-1 methyl 3-methoxy-2,6-dimethylbenzoate 
• 90925-42-1 (3-methoxy-2,6-dimethylphenyl)methanol 
• 1292688-01-7 3-(3-(tert-butyldimethylsilyloxy)-2,6-dimethylbenzyloxy)benzonitrile 
• 1292687-96-7 2-(3-(3-methoxy-2,6-dimethylbenzyloxy)-4-methylphenyl)acetic acid 
• 1292687-94-5 3-((5-(carboxymethyl)-2-methylphenoxy)methyl)-2,4-dimethylphenyl sulfate 
• 1292688-13-1 ethyl 2-(3-(3-(tert-butyldimethylsilyloxy)-2,6-dimethylbenzyloxy)-4-methylphenyl)acetate 

Relevant articles and documents

COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING β-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA

The present disclosure describes compounds and compositions that inhibit β- glucuronidase activity, and methods for attenuating the side effects of one or more drugs and improving the efficacy of drugs by administration of selective β- glucuronidase inhibitors.

COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING β-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA

The present disclosure describes compounds and compositions that inhibit β-glucuronidase activity, and methods for attenuating the side effects of one or more drugs and improving the efficacy of drugs by administration of selective β-glucuronidase inhibitors.

Imidazo[1,2-a]pyridine derivatives, methods of preparing the same and use thereof

The present invention relates to an imidazo[1,2-a]pyridine derivative, and more specifically, to an imidazo[1,2-a]pyridine derivative having excellent gastric acid secretion inhibitory activity, a method of preparing the same, and a use thereof. The imidazo[1,2-a]pyridine derivative according to the present invention has gastric acid secretion inhibitory activity, and can be usefully applied for preventing or treating gastrointestinal inflammatory diseases or gastric-related diseases.(AA) Control group(BB) Example 6(CC) Example 7(DD) Embodiment 11COPYRIGHT KIPO 2017

3-SUBSTITUTED COMPOUNDS FOR REDUCING URIC ACID

Uric acid in mammalian subjects is reduced and excretion of uric acid is increased by administering a compound of Formula 1. The uric acid-lowering effects of the compounds of this invention are used to treat or prevent a variety of conditions including g

HIV PROTEASE INHIBITORS, COMPOSITIONS CONTAINING THE SAME AND THEIR PHARMACEUTICAL USES

This invention relates to a novel series of chemical compounds useful as Human immunodeficiency Virus (HIV) protease inhibitors and to the use of such compounds as antiviral agents. The invention further relates to pharmaceutical compositions containing s

Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators

This invention is directed towards novel alkylamide derivatives as bradykinin receptor antagonists useful for the treatment of bradykinin modulated disorders such as pain, inflammation, asthma and allergy. Furthermore, the present invention is directed to novel alkylamide derivatives as bradykinin receptor agonists useful for the treatment of bradykinin modulated disorders such as hypertension and the like.

NOVEL HETEROARYL ALKYLAMIDE DERIVATIVES USEFUL AS BRADYKININ RECEPTOR MODULATORS

This invention is directed towards novel alkylamide derivatives as bradykinin receptor antagonists useful for the treatment of bradykinin modulated disorders such as pain, inflammation, asthma and allergy. Furthermore, the present invention is directed to novel alkylamide derivatives as bradykinin receptor agonists useful for the treatment of bradykinin modulated disorders such as hypertension and the like.

Heterocyclic compounds as bradykinin antagonists

This invention relates to a compound of the formula: wherein A1is lower alkylene, R1is substituted quinolyl, etc., R2is hydrogen, halogen or lower alkyl, R3is halogen or lower alkyl, and R4is a group

Benzyloxy-substituted, fused N-heterocycles, processes for their preparation, and their use as bradykinin receptor antagonists

Benzyloxy-substituted, fused N-heterocycles, because of their ability to act as bradykinin receptor antagonists, have been found to be useful as therapeutics for the treatment and prevention of liver cirrhosis or Alzheimer''s disease. This application describes such compounds, as well as processes for their preparation and use. The compounds according to this invention include compounds of formula (I) STR1in which B, D, R 1, and R 2 have the meanings indicated herein.

Novel series of O-substituted 8-quinolines and 4-benzothiazoles as potent antagonists of the bradykinin B2 receptors

The synthesis and the SAR study of novel O-substituted 8-quinolines and 4-benzothiazoles as highly potent non-peptide bradykinin B2 receptor antagonists are described. Several members of this series of antagonists efficiently inhibited the BK-induced vasoconstriction on different isolated organ preparations.